Diagnostics News and Research

RSS

Global malaria R&D funding has received sustained growth, report says

"Annual funding for research and development (R&D) in the fight against malaria has quadrupled over 16 years, generating the strongest pipeline of potential treatments in history, according to a report on Tuesday," Reuters reports.

30 Jun 2011

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma.

30 Jun 2011

Researchers develop way to uncover evolution of human cancer cells

A team of researchers led by scientists at the University of California, San Francisco has developed a way to uncover the evolution of human cancer cells, determining the order in which mutations emerge in them as they wend their way from a normal, healthy state into invasive, malignant masses.

30 Jun 2011

Boston University, University of Utah Foundation and Allegro enter license agreement for molecular testing platform

Allegro Diagnostics today announced that the company has entered into an exclusive license agreement with Boston University and the University of Utah Foundation for intellectual property related to the company's molecular testing platform. This platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer.

30 Jun 2011

China Health first quarter gross revenues increase 52% to $6.759 million

China Health Labs & Diagnostics Ltd. is pleased to announce the financial results for the first quarter ended March 31, 2011.

29 Jun 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

Start of clinical validation study of Down’s syndrome diagnostic test

In conjunction with several Central European prenatal centers, scientists at GATC Biotech AG and LifeCodexx AG have begun the clinical validation study of a non-invasive, prenatal diagnostic test based on next generation sequencing.

28 Jun 2011

454 Life Sciences launches new GS FLX+ System for high-throughput sequencing

454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS FLX+ System, an instrument capable of generating extra-long sequencing reads up to 1,000 by in length.

28 Jun 2011

QIAGEN's common shares added to U.S. Russell indexes

QIAGEN N.V. today announced that its common shares were added to the U.S. large-cap Russell 1000 Index and the broad-market Russell 3000 Index.

From QIAGEN Manchester Limited 28 Jun 2011

Kindstar, Mayo Clinic enter multiyear agreement to offer specialized laboratory support

Mayo Clinic today announced that it has entered into a multiyear agreement with Wuhan Kindstar Globalgene Technology, Inc. (Kindstar) to provide specialized laboratory support based on provision of knowledge from Mayo Clinic's Department of Laboratory Medicine and Pathology and its reference laboratory, Mayo Medical Laboratories.

28 Jun 2011

Luminex acquires EraGen Biosciences

Luminex Corporation today announced the completion of its acquisition of privately-held EraGen Biosciences, Inc., an innovator in molecular diagnostic testing technologies for infectious disease and genetic applications, for $34 million in cash.

From Luminex 28 Jun 2011

NovaSom completes $35M equity financing led by Safeguard Scientifics

NovaSom, Inc., the market leader in technology-driven, payer-aligned cost-saving solutions for Obstructive Sleep Apnea (OSA) management, today announced it has closed $35 million in equity financing.

27 Jun 2011

Endo recalls two lots of Endocet Tablets

Endo Pharmaceuticals today issued a voluntary nationwide consumer level recall of Endocet (oxycodone/acetaminophen, USP) Tablets, 10 mg/325 mg 100 count bottles, NDC 60951-712-70, Lot # 402415NV and #402426NV.

27 Jun 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Astronomers to develop potential new cancer radiation treatment

Astronomers' research on celestial bodies may have an impact on the human body. Ohio State University astronomers are working with medical physicists and radiation oncologists to develop a potential new radiation treatment - one that is intended to be tougher on tumors, but gentler on healthy tissue.

27 Jun 2011

Short-term lowering of PreDx DRS may reduce risk of developing diabetes

Data presented today from an analysis of samples from the European Diabetes Prevention Study (EDIPS) showed that the PreDx Diabetes Risk Score (DRS) is lowered by lifestyle intervention, which correlates to a reduction in the risk that patients will develop diabetes over time.

27 Jun 2011

New automated sample preparation system developed for proteomic biomarker discovery and validation

A new automated sample preparation system based on Tecan's Freedom EVO- 200 liquid handling platform has been developed for proteomic biomarker discovery and validation in collaboration with the Translational Genomics Research Institute (TGen) and the Biodesign Institute at Arizona State University.

24 Jun 2011

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo Pharmaceuticals announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted.

24 Jun 2011

ITG researchers uncover unexpected sex between two different parasites

What we anxiously fear in the influenza virus - a cross between two strains, resulting in a new variant we have no resistance against - has occurred in another pathogen, the Leishmania parasite. This was uncovered by researchers of the Institute of Tropical Medicine.

24 Jun 2011